Pfizer
NYSE:PFE Community- 2 Narratives written by author
- 1 Comments on narratives written by author
- 561 Fair Values set on narratives written by author
FR
Francisco
Community Contributor
Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency
I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines.
View narrativeUS$30.62
FV
16.0% undervalued intrinsic discount11.82%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
13 days ago author updated this narrative
WA
Consensus Narrative from 20 Analysts
TALZENNA And XTANDI Breakthroughs, Plus Vaccine Innovations, Will Drive Strong Revenue Growth
Key Takeaways Pfizer's oncology breakthroughs and new therapies in unmet needs signal strong revenue growth potential in cancer and other significant treatment markets. Vaccine pipeline advancements and strategic product initiatives are set to drive sustained revenue growth through market expansion and increased operational efficiencies.
View narrativeUS$31.32
FV
17.9% undervalued intrinsic discount-0.88%
Revenue growth p.a.
4users have liked this narrative
0users have commented on this narrative
365users have followed this narrative
Updated narrative